Inhibikase grants inducement stock options for 128,000 shares to new hires at $2.055 each

• Inhibikase Therapeutics granted non-qualified stock options covering 128,000 shares to two newly hired non-executive employees.
• Options priced at $2.055 per share, matching the Sept. 30, 2026 closing price; 10-year term.
• Vesting schedule: 25% after one year; remaining 75% in 36 equal monthly installments.
• Awards issued under the company’s 2026 Inducement Equity Plan, effective Sept. 30, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inhibikase Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610021601PRIMZONEFULLFEED9838783) on October 02, 2026, and is solely responsible for the information contained therein.